IRMD Stock iRadimed (IRMD, $87.47) Moving Average Convergence Divergence (MACD) Histogram turned positive on August 26, 2026
at Tickeron.com
This is a Bullish indicator signaling IRMD's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 54 similar cases where IRMD's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:
IRMD's Stochastic Oscillator is staying in oversold zone for 8 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRMD advanced for three days, in 197 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
IRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRMD as a result. In 79 of 114 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for IRMD turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 27 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.
The 50-day moving average for IRMD moved below the 200-day moving average on August 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
The Aroon Indicator for IRMD entered a downward trend on September 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.373) is normal, around the industry mean (10.728). P/E Ratio (46.106) is within average values for comparable stocks, (68.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.677). Dividend Yield (0.009) settles around the average of (0.018) among similar stocks. P/S Ratio (12.300) is also within normal values, averaging (39.507).
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. IRMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.